SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GZMO
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (119)10/18/1999 2:18:00 PM
From: scaram(o)uche  Read Replies (1) of 438
 
>> Pick 4 1/2, and the 60M is 13.3M shares. <<

I got a couple of private messages saying "huh?".

What I meant was..... at Friday's close, one would have had to sell about 13.3 million shares to raise just the 60M. We (shareholders) got the CEGE assets and the cash for 12.5 million shares.

Hope that's clear this time.

It will be very interesting to see the design of the ATIII trials. Any Regulatory types out there who see a good reason that GZMO/GZTC shouldn't be out talking with FDA BMY and PGNX, all at the same time? I am not nuts about GMK, but...... if it's approved, it seems like Agouron and GZMO should be climbing all over the op to test combined therapies. It also seems that FDA should be flexible and fast to smile upon such concepts.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News